These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11927094)

  • 41. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
    Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
    Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I; Tough S; Gillis L; Majaesic C
    Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factors impacting compliance with palivizumab prophylaxis.
    Pignotti MS; Indolfi G; Donzelli G
    Pediatr Infect Dis J; 2004 Feb; 23(2):186-7. PubMed ID: 14872196
    [No Abstract]   [Full Text] [Related]  

  • 44. [Current news about epidemiology of syncytial respiratory virus infection].
    Palumbo E
    Recenti Prog Med; 2008 May; 99(5):237-9. PubMed ID: 18581965
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunoprophylaxis of respiratory syncytial virus infection.
    Simoes EA
    Indian Pediatr; 2000 Mar; 37(3):243-7. PubMed ID: 10750065
    [No Abstract]   [Full Text] [Related]  

  • 46. Prevention of respiratory syncytial virus infection in high risk infants.
    Prince AM; Jacobs RF
    J Ark Med Soc; 2001 Oct; 98(4):115-8. PubMed ID: 11594047
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden.
    Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J
    Acta Paediatr; 2004 Nov; 93(11):1470-3. PubMed ID: 15513574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevention in respiratory syncytial virus infections.
    Wolfs TF; Kimpen JL
    Pediatr Pulmonol; 2001; Suppl 23():86-7. PubMed ID: 11886161
    [No Abstract]   [Full Text] [Related]  

  • 49. Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes.
    Hand IL; Noble L; Geiss D; Shotkin A
    Pediatr Infect Dis J; 2008 Feb; 27(2):175-6. PubMed ID: 18174866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting].
    Hascoet JM; Fagnani F; Charlemagne A; Vieux R; Rozé JC; Bendjenana H
    Arch Pediatr; 2008 Dec; 15(12):1739-48. PubMed ID: 18990549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.
    Grimaldi M; Gouyon B; Sagot P; Quantin C; Huet F; Gouyon JB;
    Pediatr Pulmonol; 2007 Mar; 42(3):189-92. PubMed ID: 17243184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.
    Vogel AM; Lennon DR; Broadbent R; Byrnes CA; Grimwood K; Mildenhall L; Richardson V; Rowley S
    J Paediatr Child Health; 2002 Dec; 38(6):550-4. PubMed ID: 12410864
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody.
    DeVincenzo JP; Aitken J; Harrison L
    J Pediatr; 2003 Jul; 143(1):123-6. PubMed ID: 12915838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine.
    Krilov LR; Weiner LB; Yogev R; Fergie J; Katz BZ; Henrickson KJ; Welliver RC
    Pediatrics; 2009 Dec; 124(6):1682-4. PubMed ID: 19948634
    [No Abstract]   [Full Text] [Related]  

  • 55. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
    Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
    Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Palivizumab.
    Gupta D; Gupta P
    Indian Pediatr; 2001 Nov; 38(11):1265-9. PubMed ID: 11721066
    [No Abstract]   [Full Text] [Related]  

  • 57. [Indications and prescription modalities of palivizumab in neonates].
    Guillois B
    Arch Pediatr; 2007 Sep; 14 Suppl 1():S16-23. PubMed ID: 17939952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)].
    Pin I; Pilenko C; Bost M
    Allerg Immunol (Paris); 2002 Dec; 34(10):371-4. PubMed ID: 12575622
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
    Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.